CD38 and acute myeloid leukemia: Compared the traditional FC-based MRD assay with the LSC-based approach by Zeijlemaker et al. in AML patients post-allogeneic transplantation. LSC marker expression within the CD34+CD38− compartment remained stable up to 1 year after transplant. Detection of CD34+CD38− LSCs after allografting was useful for predicting relapse, but not for leukemia-free survival or overall survival